The identification and characterization of gene signatures, driver events, and pharmacogenomics in molecularly homogeneous subsets of patients is likely to advance effective drug development strategies in colorectal cancer.
Josep Tabernero, MD, PhD
Advertisement
Articles by Josep Tabernero, MD, PhD
Advertisement
Latest Updated Articles
- Genomic Testing in Colorectal Cancer: How Much Is Enough?
Published: March 15th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
2
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
3
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
4
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
5
